MeiraGTx Holdings plc
MGTXDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
9dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
MGTX Earnings Report
EPS Est: $-0.39 | FQ end 2026-06
How MGTX's past catalysts played out
adeno-associated virus vector AAV- CNGA3
Achromatopsia
AAV - CNGB3
Achromatopsia
AAV RPE65
Leber Congenital Amaurosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
adeno-associated virus vector AAV- CNGA3 | Phase 2 | Achromatopsia | - | - |
AAV - CNGB3 | Phase 2 | Achromatopsia | - | - |
AAV RPE65 | Phase 2 | Leber Congenital Amaurosis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in MeiraGTx Holdings plc's drug pipeline?→
CatalystAlert tracks 3 drug candidates in MeiraGTx Holdings plc's (MGTX) pipeline across Phase 2. Its lead program is adeno-associated virus vector AAV- CNGA3 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MeiraGTx Holdings plc's next FDA catalyst?→
MeiraGTx Holdings plc's (MGTX) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MGTX biotech catalysts?→
Add MGTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MeiraGTx Holdings plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.